DEG6498
Phase 1Small molecule
DEG6498 is one of 21 small molecule programs targeting Malignant Neoplasm. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Malignant Neoplasm
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Aromasin
PfizerPhase 2
Nolvadex
AstraZenecaPhase 2
Femara
NovartisPhase 2
Erbitux
IImclone
Phase 2
Paraplatin
AAvyxa
Phase 2
Alimta
EEagle Pharmaceuticals, Inc.
Phase 2
Faslodex
FFresenius Kabi USA, LLC
Phase 2
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Alimta
SShawn Eagle
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DEG6498. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDegron Therapeutics Co.